TGTX TG THERAPEUTICS, INC.
Q3 2025 10-Q
TG THERAPEUTICS, INC. (TGTX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New risk: post-marketing requirements for BRIUMVI including long-term safety studies and pediatric/pregnancy evaluation triggered by FDA approval conditions
- • Most updated risk: commercialization challenges due to expanding global operations; BRIUMVI launched in Europe Feb 2024 with risks in third-party partnerships impacting sales control
Quarterly Financial SummaryXBRL
Revenue
$162M
Net Income
$391M
Operating Margin
18.2%
Net Margin
241.7%
ROE
64.4%
Total Assets
$1.0B
Source: XBRL data from TG THERAPEUTICS, INC. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on TG THERAPEUTICS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.